Last 12 months
Inside the activity.
2 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 15 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 29 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 31 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 11 |
| Jul 2026 | 2 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 25, 2020 Filed Nov 30, 2020 23:46 UTC |
Geary Richard SEVP, Development
|
SaleCommon Stock | 11,920 | $50.05 | $596,596.00 |
DisclosureSEC source: 0000874015-20-000156 · edgar.xml · nonDerivative · entry 2 Geary Richard S · CIK 0001442730 · EVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,447 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 7, 2019. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.85 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 23:46 UTC |
Geary Richard SEVP, Development
|
Exercise / conversionCommon Stock | 11,920 | $39.87 | $475,250.40 |
DisclosureSEC source: 0000874015-20-000156 · edgar.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 7, 2019. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 23:44 UTC |
PARSHALL B LYNNEDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,590 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000154 · edgar.xml · derivative · entry 3 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 23:44 UTC |
PARSHALL B LYNNEDirector
|
SaleCommon Stock | 3,590 | $50.05 | $179,679.50 |
DisclosureSEC source: 0000874015-20-000154 · edgar.xml · nonDerivative · entry 2 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,464 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.85-$50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 23:44 UTC |
PARSHALL B LYNNEDirector
|
Exercise / conversionCommon Stock | 3,590 | $39.87 | $143,133.30 |
DisclosureSEC source: 0000874015-20-000154 · edgar.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:04 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,590 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · derivative · entry 10 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,990 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:04 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 2,590 | $50.83 | $131,649.70 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · nonDerivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,021 F4 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019. F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.50 to $51.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) of this Form 4. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:04 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
Exercise / conversionCommon Stock | 2,590 | $39.87 | $103,263.30 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · nonDerivative · entry 5 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:02 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,320 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000150 · edgar.xml · derivative · entry 9 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,680 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:02 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
SaleCommon Stock | 4,320 | $50.83 | $219,585.60 |
DisclosureSEC source: 0000874015-20-000150 · edgar.xml · nonDerivative · entry 6 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,495 F5 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 2, 2020. F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.50 to $51.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) of this Form 4. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:02 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionCommon Stock | 4,320 | $39.87 | $172,238.40 |
DisclosureSEC source: 0000874015-20-000150 · edgar.xml · nonDerivative · entry 5 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 2, 2020. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 23:58 UTC |
Geary Richard SEVP, Development
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,380 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000148 · edgar.xml · derivative · entry 6 Geary Richard S · CIK 0001442730 · EVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,920 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 23:58 UTC |
Geary Richard SEVP, Development
|
SaleCommon Stock | 2,380 | $50.83 | $120,975.40 |
DisclosureSEC source: 0000874015-20-000148 · edgar.xml · nonDerivative · entry 4 Geary Richard S · CIK 0001442730 · EVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,447 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 7, 2019. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.50 to $51.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) of this Form 4. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 23:58 UTC |
Geary Richard SEVP, Development
|
Exercise / conversionCommon Stock | 2,380 | $39.87 | $94,890.60 |
DisclosureSEC source: 0000874015-20-000148 · edgar.xml · nonDerivative · entry 3 Geary Richard S · CIK 0001442730 · EVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 7, 2019. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 23:56 UTC |
PARSHALL B LYNNEDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 710 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000146 · edgar.xml · derivative · entry 6 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,590 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 23:56 UTC |
PARSHALL B LYNNEDirector
|
SaleCommon Stock | 710 | $50.82 | $36,082.20 |
DisclosureSEC source: 0000874015-20-000146 · edgar.xml · nonDerivative · entry 4 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,464 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.50 to $51.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) of this Form 4. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 23:56 UTC |
PARSHALL B LYNNEDirector
|
Exercise / conversionCommon Stock | 710 | $39.87 | $28,307.70 |
DisclosureSEC source: 0000874015-20-000146 · edgar.xml · nonDerivative · entry 3 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:04 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,600 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · derivative · entry 9 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,580 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:04 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · derivative · entry 8 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:04 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 11,600 | $50.11 | $581,276.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,021 F4 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) of this Form 4. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:04 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
Exercise / conversionCommon Stock | 11,600 | $39.87 | $462,492.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:04 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 500 | $50.00 | $25,000.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 1,581 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on March 13, 2019. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:04 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
Exercise / conversionCommon Stock | 500 | $39.87 | $19,935.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 2,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on March 13, 2019. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:02 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,875 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000150 · edgar.xml · derivative · entry 8 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:02 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 13,125 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000150 · edgar.xml · derivative · entry 7 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,875 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:02 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
SaleCommon Stock | 5,875 | $50.11 | $294,396.25 |
DisclosureSEC source: 0000874015-20-000150 · edgar.xml · nonDerivative · entry 4 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,495 F5 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 2, 2020. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:02 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionCommon Stock | 5,875 | $39.87 | $234,236.25 |
DisclosureSEC source: 0000874015-20-000150 · edgar.xml · nonDerivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 2, 2020. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:02 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
SaleCommon Stock | 13,125 | $50.11 | $657,693.75 |
DisclosureSEC source: 0000874015-20-000150 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,495 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 3, 2015. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:02 UTC |
HOUGEN ELIZABETH LEVP, Finance & CFO
|
Exercise / conversionCommon Stock | 13,125 | $39.87 | $523,293.75 |
DisclosureSEC source: 0000874015-20-000150 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 3, 2015. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 23:58 UTC |
Geary Richard SEVP, Development
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,700 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000148 · edgar.xml · derivative · entry 5 Geary Richard S · CIK 0001442730 · EVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,300 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 23:58 UTC |
Geary Richard SEVP, Development
|
SaleCommon Stock | 10,700 | $50.11 | $536,177.00 |
DisclosureSEC source: 0000874015-20-000148 · edgar.xml · nonDerivative · entry 2 Geary Richard S · CIK 0001442730 · EVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,447 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 7, 2019. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 23:58 UTC |
Geary Richard SEVP, Development
|
Exercise / conversionCommon Stock | 10,700 | $39.87 | $426,609.00 |
DisclosureSEC source: 0000874015-20-000148 · edgar.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · EVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 7, 2019. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 23:56 UTC |
PARSHALL B LYNNEDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,200 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000146 · edgar.xml · derivative · entry 5 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,300 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 23:56 UTC |
PARSHALL B LYNNEDirector
|
SaleCommon Stock | 3,200 | $50.12 | $160,384.00 |
DisclosureSEC source: 0000874015-20-000146 · edgar.xml · nonDerivative · entry 2 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,464 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 23:56 UTC |
PARSHALL B LYNNEDirector
|
Exercise / conversionCommon Stock | 3,200 | $39.87 | $127,584.00 |
DisclosureSEC source: 0000874015-20-000146 · edgar.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 11, 2020. Read SEC document |
| November 19, 2020 Filed Jan 7, 2021 02:17 UTC |
CROOKE STANLEY TDirector · Executive Chairman of Board
|
GiftCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-21-000015 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 569,391 F1 · kind: Represents a bona fide gift to a charitable organization. Read SEC document |
| November 03, 2020 Filed Nov 6, 2020 01:26 UTC |
BENNETT C FRANKChief Scientific Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000144 · edgar.xml · derivative · entry 3 BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2020 Filed Nov 6, 2020 01:26 UTC |
BENNETT C FRANKChief Scientific Officer
|
SaleCommon Stock | 15,000 | $46.77 | $701,599.50 |
DisclosureSEC source: 0000874015-20-000144 · edgar.xml · nonDerivative · entry 2 BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,476 F1 · shares: Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.50-$46.90, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. Read SEC document |
| November 03, 2020 Filed Nov 6, 2020 01:26 UTC |
BENNETT C FRANKChief Scientific Officer
|
Exercise / conversionCommon Stock | 15,000 | $39.87 | $598,050.00 |
DisclosureSEC source: 0000874015-20-000144 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 21:36 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 2,889 | $46.86 | $135,385.76 |
DisclosureSEC source: 0000874015-20-000138 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,794 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.33 to $47.15, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4 Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 21:50 UTC |
Hayden Michael RDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 1,778 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000136 · edgar.xml · derivative · entry 2 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,554 Underlying: Common Stock · 1,778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 21:50 UTC |
Hayden Michael RDirector
|
Exercise / conversionCommon Stock | 1,778 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000136 · edgar.xml · nonDerivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 21:46 UTC |
Reikes Peter NDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 1,778 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000133 · edgar.xml · derivative · entry 2 Reikes Peter N · CIK 0001753652 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,554 Underlying: Common Stock · 1,778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 21:46 UTC |
Reikes Peter NDirector
|
Exercise / conversionCommon Stock | 1,778 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000133 · edgar.xml · nonDerivative · entry 1 Reikes Peter N · CIK 0001753652 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 22:44 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 50,000 | $50.41 | $2,520,460.00 |
DisclosureSEC source: 0000874015-20-000131 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 650,391 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.02 to $50.70, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) of this Form 4 Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 22:44 UTC |
CROOKE STANLEY TDirector · Exec Chairman of the Board
|
SaleCommon Stock | 2,000 | $50.18 | $100,360.00 |
DisclosureSEC source: 0000874015-20-000131 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 1,581 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on January 2, 2020. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:45 UTC |
WENDER JOSEPH HDirector
|
Exercise / conversionDirector Stock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $28.47 | $0.00 |
DisclosureSEC source: 0000874015-20-000129 · edgar.xml · derivative · entry 4 WENDER JOSEPH H · CIK 0001073384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2023-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:45 UTC |
WENDER JOSEPH HDirector
|
Exercise / conversionDirector Stock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $12.94 | $0.00 |
DisclosureSEC source: 0000874015-20-000129 · edgar.xml · derivative · entry 3 WENDER JOSEPH H · CIK 0001073384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2022-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:45 UTC |
WENDER JOSEPH HDirector
|
Exercise / conversionCommon Stock | 11,250 | $28.47 | $320,287.50 |
DisclosureSEC source: 0000874015-20-000129 · edgar.xml · nonDerivative · entry 2 WENDER JOSEPH H · CIK 0001073384 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Joseph H. Wender Trust Disclosed balance after: 88,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option. F1 · shares: Acquired as a result of exercising a stock option. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:45 UTC |
WENDER JOSEPH HDirector
|
Exercise / conversionCommon Stock | 11,250 | $12.94 | $145,575.00 |
DisclosureSEC source: 0000874015-20-000129 · edgar.xml · nonDerivative · entry 1 WENDER JOSEPH H · CIK 0001073384 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Joseph H. Wender Trust Disclosed balance after: 77,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option. F1 · shares: Acquired as a result of exercising a stock option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.